Does eprosartan improve organoprotective surrogate markers in patients with chronic glomerulonephritis?
Eprosartan may provide renal and cardiovascular protective effects in patients with chronic glomerulonephritis, though larger controlled trials are needed.
The 12-week open uncontrollable study of eprosartan organoprotective efficacy was performed in 15 patients with chronic glomerulonephritis. Study results showed high organoprotective efficacy of eprosartan, prescribed in a dose of 600 mg daily, which is expressed as anti-proteinuric, anti-hematuric actions, positive dynamics of intraglomerular hemodynamics parameters, decreased left ventricular hypertrophy and stiffness and also normalized vasomotoric functions of brachial artery endothelium.
Kalyuzhina et al. (Fri,) studied this question.